Picture of Nyxoah SA logo

NYXH — Nyxoah SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Brief: Nyxoah: FDA IDE Approval To Initiate ACCESS Study Of Genio In Complete Concentric Collapse Patients

July 11 (Reuters) - Nyxoah SA  NYXH.BR :
    * NYXOAH RECEIVES FDA IDE APPROVAL TO INITIATE THE ACCCESS
STUDY
OF GENIO IN COMPLETE CONCENTRIC COLLAPSE PATIENTS
    * FIRST PATIENT IS EXPECTED TO BE IMPLANTED DURING Q4 OF
2022,
IN-LINE WITH PRIOR GUIDANCE
    * SEEING OUTSTANDING RESULTS IN CCC PATIENTS TREATED WITH
GENIO IN
EUROPE AND ARE EXCITED TO BEGIN ACCCESS STUDY - CEO
    * TO EVALUATE USE OF GENIO SYSTEM TO TREAT ADULT PATIENTS
WITH
MODERATE-TO-SEVERE OSA AND COMPLETE CONCENTRIC COLLAPSE (CCC) OF
SOFT PALATE
    * IN ACCCESS TRIAL, NYXOAH WILL IMPLANT UP TO 106 PATIENTS
WITH
CO-PRIMARY EFFICACY ENDPOINTS OF APNEA-HYPOPNEA INDEX (AHI)
RESPONDER RATE AND OXYGEN DESATURATION INDEX (ODI) RESPONDER
RATE

Source text for Eikon:  ID:nGNX8CVW6m 
Further company coverage:  NYXH.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))

Recent news on Nyxoah SA

See all news